10/17/2017

New Gout Drug Krystexxa Exceeds Target

New Gout Drug Krystexxa Exceeds Target

There is increased hope for the roughly 3% of chronic, severe gout sufferers who do not respond to current gout medications. Within recent period III trials of the new gout medication Krystexxa, a great impressive 42% of refractory gout patients achieved statistically significant reductions in uric acid levels, as well as sustained them for six months. This exceeeded the target amount set for the study by the drug's manufacturer, Savient Pharmaceuticals. In comparison, individuals gout patients in the trial that received a placebo saw no reduction in uric acid levels.

When you have seriously ill people who have no options, 40 percent will be pretty good," said Dr. Michael Becker from the University of Chicago," author of the most recent study, which was published in the Journal of the American Medical Association. "Gout can be a serious and disabling disease."

Krystexxa (generic name plegloticase) had been FDA approved in 2010 based on earlier clinical trials. The brand new gout medication, which is administered by intravenous infusion, is derived from an animal hormone. The pegloticase mechanism of action is different than that of other gout drugs - it converts uric acid to a nontoxic byproduct that is easily excreted in the urine.

High Levels of Uric Acid are the Cause of Gout, an Extremely Painful Form of Arthritis

The excess acid crystallizes into hook sharp debris in the joints, usually at the bottom of the big toe. The particular uric acid can also form knobby, chalky piles called tophi. Tophi can be reabsorbed back into the body if uric acid levels are reduced. Forty percent of the trial participants with tophi knowledgeable a resolution of one or more of the lumpy deposits.

All-Natural Remedies for Gout

All-Natural Remedies for Gout

Goutezol Gout Relief is formulated with soothing botanical ingredients developed to gently support healthy uric acid metabolism. Goutezol contains only the highest quality active ingredients that have been scientifically formulated to work for the best results. Goutezol's ingredients have been used safely for hundreds of years to support healthy uric acid metabolism, helping in reducing high uric acid levels. Now they are all combined into this unique gout formula. Minimizing uric acid and supporting uric acid metabolism has been proven to alleviate the discomfort and flare-ups related to gout.
More Details about This Product »

TREATING GOUT NATURALLY VIDEO - Stop the pills and try my natural gout treatment.

http://TheGoutKiller.com There are only two ways of treating gout: with pharmaceutical drugs and pills that don't really work . . . OR . . . you can treat gout ...

Krystexxa Emerges Intravenously Over At Least Two Hours Every Two Weeks

The Fda has warned that patients should be given a corticosteroid and antihistamine before infusions as a result of high risk of allergic reaction. Other common side effects of Krystexxa are gout flare ups (which occurred in 80% of the recent trial participants), nausea and vomiting, chest pain, constipation, nasal irritation and bruising at the injection site.

  • Myths About Back Pain: Get the FactsMyths About Back Pain: Get the Facts Suffering from back pain? According to the American Chiropractic Association 31 million Americans experience low-back pain at any given time. We found this interesting slide show filled with both Misconceptions and A look at back pain on Web MD....
  • Krystexxa is not intended for use in the average gouty arthritis patient, most of which can be treated with more traditional gout medications such as Colcrys (generic colchicine) or Zyloprim (generic allopurinal). Currently, the new injectable gout drug costs about $5000 a month. It's hoped that gout patients who respond well to the treatment could eventually use cheaper gout drugs.

    Armed with these impressive new results, Savient Pharmaceuticals intends to amp up promotion of its new gout drug in the US and other countries. Up to now, their advertising efforts have largely been aimed at rheumatologists, but they now plan to expand their own efforts to include primary care physicians. "This really now is the foundation for our launch of stage 2 into the primary care audience," said Savient Chief Executive Officer John Johnson.

    Johnson says the pharmaceutical company "expects to see a few velocity inside sales" as a result of their increased target market. The company is said to be disappointed in the $1.4 million bucks in net sales the gout treatment generated in the first six months after receiving Fda approval.

    Alex Ray Advocates for Affordable Access to Healthcare and Medication

    She recommends Big Mountain Drugs as a reliable online Canadian pharmacy from which to buy colchicine as well as allopurinol regarding gout. For more information about gout and gout medication, visit the online resource www.colchicine.ca.

    PDF File Get this page as .pdf.